IDiyas

For the Inventor, By the Inventor

Wilmington, DE, United States of America

Rebecca Urbanek

USPTO Granted Patents = 12 

 

Average Co-Inventor Count = 8.1

ph-index = 2

Forward Citations = 15(Granted Patents)


Company Filing History:

goldMedal12 out of 1,500 
 
Astrazeneca Ab
 patents

Years Active: 2004-2012

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents
1. 8153638 - Metabotropic glutamate-receptor-potentiating isoindolones (2012-04-10),
2. 7968570 - Isoindolone compounds and their use as metabotropic glutamate receptor potentiators (2011-06-28),
3. 7868008 - Substituted isoindolones and their use as metabotropic glutamate receptor potentiators (2011-01-11),
4. 7842803 - Nicotinic acetylcholine receptor ligands 101 (2010-11-30),
5. 7807706 - Metabotropic glutamate-receptor-potentiating isoindolones (2010-10-05),
6. 6946463 - 1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones and their use for the treatment of pain (2005-09-20),
7. 6943165 - Compound and method for the treatment of pain (2005-09-13),
8. 6939896 - Cd45 inhibitors (2005-09-06),
9. 6933297 - 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione and the use thereof for the treatment of pain (2005-08-23),
10. 6833368 - 1, 2, 5, 10-tetrahydropyridazino[4, 5-b]quinoline-1,10-diones and their use for the treatment of pain (2004-12-21),
11. 6787547 - Compound and method for the treatment of pain (2004-09-07),
12. 6730675 - Compounds and methods for the treatment of pain (2004-05-04),

Title: Inventor Spotlight: Rebecca Urbanek

Introduction

Rebecca Urbanek, an innovative inventor based in Wilmington, DE, has made significant contributions to the field of pharmaceutical sciences. With a remarkable portfolio of 12 patents, she has demonstrated her dedication to advancing therapeutic compounds that can impact numerous medical conditions.

Latest Patents

Rebecca's latest innovations include patents for metabotropic glutamate-receptor-potentiating isoindolones. These compounds, specified by a unique formula, encompass processes for their preparation, new intermediates used in their production, and pharmaceutical compositions that utilize these compounds for therapeutic applications. Her work on isoindolone compounds further enhances our understanding and capability to use these as metabotropic glutamate receptor potentiators for various treatments.

Career Highlights

Currently employed at AstraZeneca AB, Rebecca Urbanek has created a substantial impact within the pharmaceutical sector through her inventive work. Her ability to bridge the gap between basic research and clinical application positions her as a remarkable figure in the industry. The detailed processes involved in her patents not only reflect her expertise but also her commitment to improving patient outcomes through innovative therapies.

Collaborations

Rebecca often collaborates with talented colleagues such as Gary Steelman and Thomas Michael Bare. These partnerships are vital for the cross-pollination of ideas and expertise, fostering an environment where innovation can thrive. Together, they are pushing the boundaries of what is possible in their respective fields.

Conclusion

Rebecca Urbanek exemplifies the qualities of a forward-thinking inventor. With her extensive list of patents and a strong collaborative network, she continues to pave the way for advancements in therapeutic innovations. Her contributions will undoubtedly play a crucial role in the future of medical science and patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…